Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Doctor Call Live Tomorrow Morning (6/21) Checking The Launch: How Is Ingrezza Fairing In The Early Days Of Commercialization?

|Includes: Neurocrine Biosciences, Inc. (NBIX), TEVA

Bright & Early: June 21st at 8:30am ET

Checking in on the Ingrezza Launch with a Doctor who has prescribed it to his patients

Why You Should Care:

  • Since approval various Payors have indicated they plan to restrict access to Ingrezza in sell-side surveys
  • Patient access is essential to meeting estimated sales targets for Neurocrine (NASDAQ:NBIX)
  • A debate is currently raging among some Buy-Side Investors about the need to treat Tardive Dyskinesia (NYSE:TD) at all
  • A conversation with a doctor who has 5 patients on Ingrezza already out of his 250 TD patients will help answer these questions

Join the project here:

And don't forget! A transcript of the call will be posted in the Slingshot Insights "Become the Smart Money" 4 weeks after completion! Join us today: